Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| ABBOTT LABORATORIESABT · Entity 2314 | Director | April 24, 2026 | April 28, 2026 |
| Accenture plcACN · Entity 2893 | Director | August 14, 2026 | August 17, 2026 |
| Mondelez International, Inc.MDLZ · Entity 2953 | Director | May 20, 2026 | May 21, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
ABBOTT LABORATORIES
Report date April 24, 2026 · Filed April 28, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common shares without par valueSEC Table I · non-derivative | Direct | 41,010 |
Reported balance
After 2026-04-24 transaction · row 1
1 source rowRow 1 · 2026-04-24 · Grant · Acquired 2,286 · Balance 41,010 F1: Restricted stock unit award granted under the Abbott Laboratories 2026 Incentive Stock Program (the "Program"). The award will be paid, on a one-to-one basis, in Abbott common shares on the earlier of the date of the director's separation from service, death, or the occurrence of a change in control (as defined in the Program). |
| Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $91.86 · Expires 2036-04-23 | Direct | 2,305 |
Reported balance
After 2026-04-24 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-04-24 · Grant · Acquired 2,305 · Balance 2,305 F2: Stock option granted under the Program, in a transaction exempt from Section 16 under Rule 16b-3. |
Filing footnotes · ownership attribution and instrument terms
F1: Restricted stock unit award granted under the Abbott Laboratories 2026 Incentive Stock Program (the "Program"). The award will be paid, on a one-to-one basis, in Abbott common shares on the earlier of the date of the director's separation from service, death, or the occurrence of a change in control (as defined in the Program).
F2: Stock option granted under the Program, in a transaction exempt from Section 16 under Rule 16b-3.
Accenture plc
Report date August 14, 2026 · Filed August 17, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Class A ordinary sharesSEC Table I · non-derivative | Direct | 8,107 |
Reported balance
After 2026-08-14 transaction · row 1
1 source rowRow 1 · 2026-08-14 · Grant · Acquired 12 · Balance 8,107 F1: Grant of Restricted Share Units (RSUs) pursuant to the anti-dilution provisions of previously granted RSU awards, to reflect Accenture plc's payment of a cash dividend. |
Filing footnotes · ownership attribution and instrument terms
F1: Grant of Restricted Share Units (RSUs) pursuant to the anti-dilution provisions of previously granted RSU awards, to reflect Accenture plc's payment of a cash dividend.
Mondelez International, Inc.
Report date May 20, 2026 · Filed May 21, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Class A Common StockSEC Table I · non-derivative | Direct | 6,634 |
Reported balance
After 2026-05-20 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2026-05-20 · Grant · Acquired 3,525 · Balance 6,634 F1: Grant of deferred stock units under the Issuer's 2024 Performance Incentive Plan. The deferred stock units are 100% vested, but receipt of the shares is deferred until the six-month anniversary of the reporting person's separation from service as a director of Mondelez International. F2: Total number of shares owned includes approximately 100 shares acquired through a dividend reinvestment program. |
Filing footnotes · ownership attribution and instrument terms
F1: Grant of deferred stock units under the Issuer's 2024 Performance Incentive Plan. The deferred stock units are 100% vested, but receipt of the shares is deferred until the six-month anniversary of the reporting person's separation from service as a director of Mondelez International.
F2: Total number of shares owned includes approximately 100 shares acquired through a dividend reinvestment program.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| August 13, 2021 Filed Aug 17, 2021 12:55 UTC | Accenture plc ACN · Entity 2893 | GrantClass A ordinary shares | 4 | $0.00 | $0.00 |
DisclosureSEC source: 0001467373-21-000193 · wf-form4_162920491688434.xml · nonDerivative · entry 1 McKinstry Nancy · CIK 0001294731 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,425 F1 · security: Grant of Restricted Share Units (RSUs) pursuant to the anti-dilution provisions of previously granted RSU awards, to reflect Accenture plc's payment of a cash dividend. Read SEC document |
| May 14, 2021 Filed May 17, 2021 21:28 UTC | Accenture plc ACN · Entity 2893 | GrantClass A ordinary shares | 4 | $0.00 | $0.00 |
DisclosureSEC source: 0001467373-21-000135 · wf-form4_162128688735510.xml · nonDerivative · entry 1 McKinstry Nancy · CIK 0001294731 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,421 F1 · security: Grant of Restricted Share Units (RSUs) pursuant to the anti-dilution provisions of previously granted RSU awards, to reflect Accenture plc's payment of a cash dividend. Read SEC document |
| April 23, 2021 Filed Apr 27, 2021 23:08 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GrantOption (right to buy) · Derivative | 7,035 | $0.00 Strike: $123.38 | $0.00 |
DisclosureSEC source: 0001415889-21-002159 · form4-04272021_040450.xml · derivative · entry 2 McKinstry Nancy · CIK 0001294731 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,035 Underlying: Common Shares · 7,035 shares Expires 2031-04-22 F2 · security: Stock option granted pursuant to the Abbott Laboratories 2017 Incentive Stock Program, in a transaction exempt from Section 16 under Rule 16b-3. Read SEC document |
| April 23, 2021 Filed Apr 27, 2021 23:08 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GrantCommon shares without par value | 1,499 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-21-002159 · form4-04272021_040450.xml · nonDerivative · entry 1 McKinstry Nancy · CIK 0001294731 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,139 F1 · shares: These are restricted stock units awarded under the Abbott Laboratories 2017 Incentive Stock Program (the "Program"). They will be paid, on a one-to-one basis, in Abbott common shares on the earlier of the date of the director's separation from service, death, or the occurrence of a change in control (as defined in the Program). Read SEC document |
| February 12, 2021 Filed Feb 16, 2021 14:02 UTC | Accenture plc ACN · Entity 2893 | Tax withholdingClass A ordinary shares | 2 | $257.00 | $514.00 |
DisclosureSEC source: 0001467373-21-000082 · wf-form4_161348414613762.xml · nonDerivative · entry 2 McKinstry Nancy · CIK 0001294731 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,417 Read SEC document |
| February 12, 2021 Filed Feb 16, 2021 14:02 UTC | Accenture plc ACN · Entity 2893 | GrantClass A ordinary shares | 4 | $0.00 | $0.00 |
DisclosureSEC source: 0001467373-21-000082 · wf-form4_161348414613762.xml · nonDerivative · entry 1 McKinstry Nancy · CIK 0001294731 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,419 F1 · security: Grant of Restricted Share Units (RSUs) pursuant to the anti-dilution provisions of previously granted RSU awards, to reflect Accenture plc's payment of a cash dividend. Read SEC document |
| February 03, 2021 Filed Feb 4, 2021 21:23 UTC | Accenture plc ACN · Entity 2893 | GrantClass A ordinary shares | 1,167 | $0.00 | $0.00 |
DisclosureSEC source: 0001467373-21-000056 · wf-form4_161247381515079.xml · nonDerivative · entry 1 McKinstry Nancy · CIK 0001294731 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,415 Read SEC document |
| January 30, 2021 Filed Feb 2, 2021 21:44 UTC | Accenture plc ACN · Entity 2893 | Tax withholdingClass A ordinary shares | 517 | $245.48 | $126,913.16 |
DisclosureSEC source: 0001467373-21-000036 · wf-form4_161230223730486.xml · nonDerivative · entry 1 McKinstry Nancy · CIK 0001294731 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,248 Read SEC document |
| November 13, 2020 Filed Nov 17, 2020 22:04 UTC | Accenture plc ACN · Entity 2893 | GrantClass A ordinary shares | 4 | $0.00 | $0.00 |
DisclosureSEC source: 0001467373-20-000396 · wf-form4_160565065633991.xml · nonDerivative · entry 1 McKinstry Nancy · CIK 0001294731 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,765 F1 · security: Grant of Restricted Share Units (RSUs) pursuant to the anti-dilution provisions of previously granted RSU awards, to reflect Accenture plc's payment of a cash dividend. Read SEC document |
| August 14, 2020 Filed Aug 18, 2020 12:29 UTC | Accenture plc ACN · Entity 2893 | GrantClass A ordinary shares | 4 | $0.00 | $0.00 |
DisclosureSEC source: 0001467373-20-000314 · wf-form4_159775374467617.xml · nonDerivative · entry 1 McKinstry Nancy · CIK 0001294731 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,761 F1 · security: Grant of Restricted Share Units (RSUs) pursuant to the anti-dilution provisions of previously granted RSU awards, to reflect Accenture plc's payment of a cash dividend. Read SEC document |
| May 15, 2020 Filed May 19, 2020 13:15 UTC | Accenture plc ACN · Entity 2893 | GrantClass A ordinary shares | 5 | $180.90 | $904.48 |
DisclosureSEC source: 0001467373-20-000220 · wf-form4_158989411380552.xml · nonDerivative · entry 1 McKinstry Nancy · CIK 0001294731 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,757 F1 · security: Grant of Restricted Share Units (RSUs) pursuant to the anti-dilution provisions of previously granted RSU awards, to reflect Accenture plc's payment of a cash dividend. Read SEC document |
| April 24, 2020 Filed Apr 28, 2020 21:24 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GrantOption (right to buy) · Derivative | 8,454 | $0.00 Strike: $93.68 | $0.00 |
DisclosureSEC source: 0001179110-20-005185 · edgar.xml · derivative · entry 2 McKinstry Nancy · CIK 0001294731 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,454 Underlying: Common shares · 8,454 shares Expires 2030-04-23 F2 · security: Stock option granted pursuant to the Abbott Laboratories 2017 Incentive Stock Program, in a transaction exempt from Section 16 under Rule 16b-3. Read SEC document |
| April 24, 2020 Filed Apr 28, 2020 21:24 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GrantCommon shares without par value | 1,974 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-20-005185 · edgar.xml · nonDerivative · entry 1 McKinstry Nancy · CIK 0001294731 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,640 F1 · shares: These are restricted stock units awarded under the Abbott Laboratories 2017 Incentive Stock Program (the "Program"). They will be paid, on a one-to-one basis, in Abbott common shares on the earlier of the date of the director's separation from service, death, or the occurrence of a change in control (as defined in the Program). Read SEC document |
| February 14, 2020 Filed Feb 19, 2020 21:13 UTC | Accenture plc ACN · Entity 2893 | Tax withholdingClass A ordinary shares | 4 | $212.44 | $849.77 |
DisclosureSEC source: 0001467373-20-000130 · wf-form4_158214677804628.xml · nonDerivative · entry 2 McKinstry Nancy · CIK 0001294731 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,752 Read SEC document |
| February 14, 2020 Filed Feb 19, 2020 21:13 UTC | Accenture plc ACN · Entity 2893 | GrantClass A ordinary shares | 7 | $0.00 | $0.00 |
DisclosureSEC source: 0001467373-20-000130 · wf-form4_158214677804628.xml · nonDerivative · entry 1 McKinstry Nancy · CIK 0001294731 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,756 F1 · security: Grant of Restricted Share Units (RSUs) pursuant to the anti-dilution provisions of previously granted RSU awards, to reflect Accenture plc's payment of a cash dividend. Read SEC document |
| February 01, 2020 Filed Feb 4, 2020 21:22 UTC | Accenture plc ACN · Entity 2893 | Tax withholdingClass A ordinary shares | 867 | $206.81 | $179,307.56 |
DisclosureSEC source: 0001467373-20-000073 · wf-form4_158085134224399.xml · nonDerivative · entry 1 McKinstry Nancy · CIK 0001294731 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,749 Read SEC document |
| January 30, 2020 Filed Feb 3, 2020 22:30 UTC | Accenture plc ACN · Entity 2893 | GrantClass A ordinary shares | 1,062 | $0.00 | $0.00 |
DisclosureSEC source: 0001467373-20-000058 · wf-form4_158076904156304.xml · nonDerivative · entry 1 McKinstry Nancy · CIK 0001294731 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,616 Read SEC document |
| November 15, 2019 Filed Nov 19, 2019 21:18 UTC | Accenture plc ACN · Entity 2893 | GrantClass A ordinary shares | 8 | $0.00 | $0.00 |
DisclosureSEC source: 0001467373-19-000364 · wf-form4_157419826987852.xml · nonDerivative · entry 1 McKinstry Nancy · CIK 0001294731 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,554 F1 · security: Grant of Restricted Share Units (RSUs) pursuant to the anti-dilution provisions of previously granted RSU awards, to reflect Accenture plc's payment of a cash dividend. Read SEC document |
| May 15, 2019 Filed May 17, 2019 13:07 UTC | Accenture plc ACN · Entity 2893 | GrantClass A ordinary shares | 15 | $0.00 | $0.00 |
DisclosureSEC source: 0001467373-19-000188 · wf-form4_155809841754041.xml · nonDerivative · entry 1 McKinstry Nancy · CIK 0001294731 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,546 F1 · security: Grant of Restricted Share Units (RSUs) pursuant to the anti-dilution provisions of previously granted RSU awards, to reflect Accenture plc's payment of a cash dividend. Read SEC document |
| April 26, 2019 Filed Apr 30, 2019 21:11 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GrantOption (right to buy) · Derivative | 10,146 | $0.00 Strike: $78.06 | $0.00 |
DisclosureSEC source: 0001179110-19-005302 · edgar.xml · derivative · entry 2 McKinstry Nancy · CIK 0001294731 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,146 Underlying: Common shares · 10,146 shares Expires 2029-04-25 F2 · security: Stock option granted pursuant to the Abbott Laboratories 2017 Incentive Stock Program, in a transaction exempt from Section 16 under Rule 16b-3. Read SEC document |
| April 26, 2019 Filed Apr 30, 2019 21:11 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GrantCommon shares without par value | 2,241 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-19-005302 · edgar.xml · nonDerivative · entry 1 McKinstry Nancy · CIK 0001294731 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,666 F1 · shares: These are restricted stock units awarded under the Abbott Laboratories 2017 Incentive Stock Program (the "Program"). They will be paid, on a one-to-one basis, in Abbott common shares on the earlier of the date of the director's separation from service, death, or the occurrence of a change in control (as defined in the Program). Read SEC document |
| February 07, 2019 Filed Feb 11, 2019 21:21 UTC | Accenture plc ACN · Entity 2893 | Tax withholdingClass A ordinary shares | 821 | $155.10 | $127,333.00 |
DisclosureSEC source: 0001467373-19-000104 · wf-form4_154992008433951.xml · nonDerivative · entry 1 McKinstry Nancy · CIK 0001294731 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,531 Read SEC document |
| February 01, 2019 Filed Feb 5, 2019 21:21 UTC | Accenture plc ACN · Entity 2893 | GrantClass A ordinary shares | 1,780 | $0.00 | $0.00 |
DisclosureSEC source: 0001467373-19-000072 · wf-form4_154940170395118.xml · nonDerivative · entry 1 McKinstry Nancy · CIK 0001294731 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,352 Read SEC document |
| November 15, 2018 Filed Nov 19, 2018 21:37 UTC | Accenture plc ACN · Entity 2893 | GrantClass A ordinary shares | 16 | $0.00 | $0.00 |
DisclosureSEC source: 0001467373-18-000402 · wf-form4_154266342212237.xml · nonDerivative · entry 1 McKinstry Nancy · CIK 0001294731 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,572 F1 · security: Grant of Restricted Share Units (RSUs) pursuant to the anti-dilution provisions of previously granted RSU awards, to reflect Accenture plc's payment of a cash dividend. Read SEC document |
| May 15, 2018 Filed May 17, 2018 21:58 UTC | Accenture plc ACN · Entity 2893 | GrantAccenture plc Class A ordinary shares | 15 | $0.00 | $0.00 |
DisclosureSEC source: 0001467373-18-000203 · wf-form4_152659427461639.xml · nonDerivative · entry 1 McKinstry Nancy · CIK 0001294731 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,556 F1 · security: Grant of Restricted Share Units (RSUs) pursuant to the anti-dilution provisions of previously granted RSU awards, to reflect Accenture plc's payment of a cash dividend. Read SEC document |
| April 27, 2018 Filed May 1, 2018 23:10 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GrantOption (right to buy) · Derivative | 13,328 | $0.00 Strike: $59.42 | $0.00 |
DisclosureSEC source: 0001179110-18-006026 · edgar.xml · derivative · entry 2 McKinstry Nancy · CIK 0001294731 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,328 Underlying: Common shares · 13,328 shares Expires 2028-04-26 F2 · security: Stock option granted pursuant to the Abbott Laboratories 2017 Incentive Stock Program, in a transaction exempt from Section 16 under Rule 16b-3. Read SEC document |
| April 27, 2018 Filed May 1, 2018 23:10 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GrantCommon shares without par value | 2,945 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-18-006026 · edgar.xml · nonDerivative · entry 1 McKinstry Nancy · CIK 0001294731 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,425 F1 · shares: These are restricted stock units awarded under the Abbott Laboratories 2017 Incentive Stock Program (the "Program"). They will be paid, on a one-to-one basis, in Abbott common shares on the earlier of the date of the director's separation from service, death, or the occurrence of a change in control (as defined in the Program). Read SEC document |
| February 10, 2018 Filed Feb 13, 2018 21:24 UTC | Accenture plc ACN · Entity 2893 | Tax withholdingClass A ordinary shares | 766 | $151.89 | $116,347.74 |
DisclosureSEC source: 0001467373-18-000118 · wf-form4_151855702794823.xml · nonDerivative · entry 1 McKinstry Nancy · CIK 0001294731 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,541 Read SEC document |
| February 07, 2018 Filed Feb 9, 2018 14:26 UTC | Accenture plc ACN · Entity 2893 | GrantClass A ordinary shares | 1,682 | $0.00 | $0.00 |
DisclosureSEC source: 0001467373-18-000097 · wf-form4_151818636283033.xml · nonDerivative · entry 1 McKinstry Nancy · CIK 0001294731 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,307 Read SEC document |
| November 15, 2017 Filed Nov 17, 2017 21:22 UTC | Accenture plc ACN · Entity 2893 | GrantClass A ordinary shares | 15 | $0.00 | $0.00 |
DisclosureSEC source: 0001467373-17-000473 · wf-form4_151095373872734.xml · nonDerivative · entry 1 McKinstry Nancy · CIK 0001294731 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,625 F1 · security: Grant of Restricted Share Units (RSUs) pursuant to the anti-dilution provisions of previously granted RSU awards, to reflect Accenture plc's payment of a cash dividend. Read SEC document |
| August 01, 2017 Filed Aug 3, 2017 20:31 UTC | Accenture plc ACN · Entity 2893 | Tax withholdingClass A ordinary shares | 935 | $129.42 | $121,007.70 |
DisclosureSEC source: 0001467373-17-000354 · wf-form4_150179226490151.xml · nonDerivative · entry 1 McKinstry Nancy · CIK 0001294731 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,610 Read SEC document |
| May 15, 2017 Filed May 16, 2017 20:13 UTC | Accenture plc ACN · Entity 2893 | GrantAccenture plc Class A ordinary shares | 36 | $0.00 | $0.00 |
DisclosureSEC source: 0001467373-17-000244 · wf-form4_149496560630061.xml · nonDerivative · entry 1 McKinstry Nancy · CIK 0001294731 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,545 F1 · security: Grant of Restricted Share Units (RSUs) pursuant to the anti-dilution provisions of previously granted RSU awards, to reflect Accenture plc's payment of a cash dividend. Read SEC document |
| April 28, 2017 Filed May 2, 2017 21:08 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GrantOption (right to buy) · Derivative | 18,148 | $0.00 Strike: $43.64 | $0.00 |
DisclosureSEC source: 0001179110-17-006405 · edgar.xml · derivative · entry 2 McKinstry Nancy · CIK 0001294731 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,148 Underlying: Common shares · 18,148 shares Expires 2027-04-27 F2 · security: Stock option granted pursuant to the Abbott Laboratories 2017 Incentive Stock Program, in a transaction exempt from Section 16 under Rule 16b-3. Read SEC document |
| April 28, 2017 Filed May 2, 2017 21:08 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GrantCommon shares without par value | 3,437 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-17-006405 · edgar.xml · nonDerivative · entry 1 McKinstry Nancy · CIK 0001294731 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,480 F1 · shares: These are restricted stock units awarded under the Abbott Laboratories 2017 Incentive Stock Program (the "Program"). They will be paid, on a one-to-one basis, in Abbott common shares on the earlier of the date of the director's separation from service, death, or the occurrence of a change in control (as defined in the Program). F1 · price: These are restricted stock units awarded under the Abbott Laboratories 2017 Incentive Stock Program (the "Program"). They will be paid, on a one-to-one basis, in Abbott common shares on the earlier of the date of the director's separation from service, death, or the occurrence of a change in control (as defined in the Program). Read SEC document |
| February 10, 2017 Filed Feb 13, 2017 21:23 UTC | Accenture plc ACN · Entity 2893 | GrantClass A ordinary shares | 1,572 | $0.00 | $0.00 |
DisclosureSEC source: 0001467373-17-000122 · wf-form4_148702101921463.xml · nonDerivative · entry 1 McKinstry Nancy · CIK 0001294731 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,509 Read SEC document |
| November 15, 2016 Filed Nov 17, 2016 14:18 UTC | Accenture plc ACN · Entity 2893 | GrantClass A ordinary shares | 20 | $0.00 | $0.00 |
DisclosureSEC source: 0001467373-16-001141 · wf-form4_147939228346280.xml · nonDerivative · entry 1 McKinstry Nancy · CIK 0001294731 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,937 F1 · security: Grant of Restricted Share Units (RSUs) pursuant to the anti-dilution provisions of previously granted RSU awards, to reflect Accenture plc's payment of a cash dividend. Read SEC document |
| April 29, 2016 Filed May 3, 2016 21:25 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GrantCommon shares without par value | 3,799 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-16-023677 · edgar.xml · nonDerivative · entry 1 McKinstry Nancy · CIK 0001294731 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,043 F1 · shares: These are restricted stock units awarded under the Abbott Laboratories 2009 Incentive Stock Program (the "Program"). They will be paid, on a one-to-one basis, in Abbott common shares on the earlier of the date of the director's separation from service, death, or the occurrence of a change in control (as defined in the Program). F1 · price: These are restricted stock units awarded under the Abbott Laboratories 2009 Incentive Stock Program (the "Program"). They will be paid, on a one-to-one basis, in Abbott common shares on the earlier of the date of the director's separation from service, death, or the occurrence of a change in control (as defined in the Program). Read SEC document |
| April 24, 2015 Filed Apr 28, 2015 21:13 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GrantCommon shares without par value | 2,793 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-15-006743 · edgar.xml · nonDerivative · entry 1 McKinstry Nancy · CIK 0001294731 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,244 F1 · kind: These are restricted stock units awarded under the Abbott Laboratories 2009 Incentive Stock Program (the "Program"). They will be paid, on a one-to-one basis, in Abbott common shares on the earlier of the date of the director's separation from service, death, or the occurrence of a change in control (as defined in the Program). F1 · price: These are restricted stock units awarded under the Abbott Laboratories 2009 Incentive Stock Program (the "Program"). They will be paid, on a one-to-one basis, in Abbott common shares on the earlier of the date of the director's separation from service, death, or the occurrence of a change in control (as defined in the Program). Read SEC document |
| April 25, 2014 Filed Apr 29, 2014 21:18 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GrantCommon shares without par value | 3,535 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-14-007336 · edgar.xml · nonDerivative · entry 1 McKinstry Nancy · CIK 0001294731 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,451 F1 · kind: These are restricted stock units awarded under the Abbott Laboratories 2009 Incentive Stock Program (the "Program"). They will be paid, on a one-to-one basis, in Abbott common shares on the earlier of the date of the director's separation from service, death, or the occurrence of a change in control (as defined in the Program). F1 · price: These are restricted stock units awarded under the Abbott Laboratories 2009 Incentive Stock Program (the "Program"). They will be paid, on a one-to-one basis, in Abbott common shares on the earlier of the date of the director's separation from service, death, or the occurrence of a change in control (as defined in the Program). Read SEC document |
| April 26, 2013 Filed Apr 30, 2013 21:11 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GrantCommon shares without par value | 3,097 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-13-007414 · edgar.xml · nonDerivative · entry 1 McKinstry Nancy · CIK 0001294731 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,916 F1 · kind: These are restricted stock units awarded under the Abbott Laboratories 2009 Incentive Stock Program (the "Program"). They will be paid, on a one-to-one basis, in Abbott common shares on the earlier of the date of the director's separation from service, death, or the occurrence of a change in control (as defined in the Program). F1 · price: These are restricted stock units awarded under the Abbott Laboratories 2009 Incentive Stock Program (the "Program"). They will be paid, on a one-to-one basis, in Abbott common shares on the earlier of the date of the director's separation from service, death, or the occurrence of a change in control (as defined in the Program). Read SEC document |
| April 27, 2012 Filed May 1, 2012 21:09 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GrantOption (right to buy) · Derivative | 6,280 | $0.00 Strike: $62.10 | $0.00 |
DisclosureSEC source: 0001179110-12-007450 · edgar.xml · derivative · entry 2 McKinstry Nancy · CIK 0001294731 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,280 Underlying: Common shares · 6,280 shares Expires 2022-04-26 F2 · security: Stock option granted pursuant to the Abbott Laboratories 2009 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. Read SEC document |
| April 27, 2012 Filed May 1, 2012 21:09 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GrantCommon shares without par value | 1,819 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-12-007450 · edgar.xml · nonDerivative · entry 1 McKinstry Nancy · CIK 0001294731 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,819 F1 · kind: These are restricted stock units awarded under the Abbott Laboratories 2009 Incentive Stock Program (the "Program"). They will be paid, on a one-to-one basis, in Abbott common shares on the earlier of the date of the director's separation from service, death, or the occurrence of a change in control (as defined in the Program). F1 · price: These are restricted stock units awarded under the Abbott Laboratories 2009 Incentive Stock Program (the "Program"). They will be paid, on a one-to-one basis, in Abbott common shares on the earlier of the date of the director's separation from service, death, or the occurrence of a change in control (as defined in the Program). Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.